New Capabilities aim to strengthen corporate profile for strategic transactions and reinforce ongoing partnering discussions
TME Pharma N.V., a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced a collaboration with aimed analytics, a cutting-edge medical data analytics company. This partnership supports TME Pharma’s strategic plan, announced on December 4, 2024, by enhancing its capability profile for potential strategic partners.
This partnership aims to leverage artificial intelligence (AI) to create new and improved drug candidates without the need for time and resource-intensive laboratory testing. The collaboration leverages recent cutting-edge advances in AI to accelerate timelines while reducing associated costs and need for experimental infrastructure.
Also Read: AlphaMeld Expands Collaboration with Kyowa Kirin for Drug Discovery Platform
“The 2024 Nobel Prize in Chemistry was awarded for AI-based models that allow remarkable prediction of molecular structures. This technology can also be used to discover new drugs and improved versions of existing drugs. We believe that the collaboration with aimed analytics will further advance our strategic vision announced last December. By combining our expertise in development of oligonucleotide drugs, cancer biology and immune-oncology with aimed analytics’ cutting-edge capabilities, we aim to integrate AI- and Deep Learning-driven insights into our drug discovery capabilities,” said Aram Mangasarian, CEO of TME Pharma. “The goal of this collaboration is to allow TME Pharma to not only bring its existing drugs to the table for strategic partners, but also the potential for rapid and efficient discovery of new drugs. We are committed to delivering on the goals of our new strategy announced in December 2024 and plan to share further information about our progress in the coming weeks.”
“We are excited to partner with TME Pharma and contribute our deep-learning and structural modelling expertise to their innovative approach in cancer treatment,” saidDr. Patrick Günther, CEO of aimed analytics. “By enabling a comprehensive search for promising therapeutic compounds and bringing a new level of technological sophistication to TME Pharma‘s drug discovery efforts, we aim to accelerate the discovery of more effective treatments and potentially lead to breakthrough therapies for patients in need.”
Source: Businesswire
